Show simple item record

dc.contributor.authorMorris, Olivia Cen
dc.contributor.authorElsawy, Men
dc.contributor.authorFairclough, Men
dc.contributor.authorWilliams, Kaye Jen
dc.contributor.authorMcMahon, Adamen
dc.contributor.authorGrigg, Jen
dc.contributor.authorForster, Duncanen
dc.contributor.authorMiller, Aen
dc.contributor.authorSaiani, Aen
dc.contributor.authorPrenant, Christianen
dc.date.accessioned2017-09-22T15:41:22Z
dc.date.available2017-09-22T15:41:22Z
dc.date.issued2017-08
dc.identifier.citationIn vivo characterisation of a therapeutically relevant self-assembling (18) F-labelled β-sheet forming peptide and its hydrogel using positron emission tomography. 2017, 60 (10):481-488 J Labelled Comp Radiopharmen
dc.identifier.issn1099-1344
dc.identifier.pmid28623878
dc.identifier.doi10.1002/jlcr.3534
dc.identifier.urihttp://hdl.handle.net/10541/620572
dc.description.abstractPositron emission tomography (PET) and fluorescence labelling have been used to assess the pharmacokinetics, biodistribution and eventual fate of a hydrogel-forming nonapeptide, FEFKFEFKK (F9), in healthy mice, using (18) F-labelled and fluorescein isothiocyanate (FITC)-labelled F9 analogues. F9 was site-specifically radiolabelled with 2-[(18) F]fluoro-3-pyridinecarboxaldehyde ([(18) F]FPCA) via oxime bond formation. [(18) F]FPCA-F9 in vivo fate was evaluated both as a solution, following intravenous administration, and as a hydrogel when subcutaneously injected. The behaviour of FITC-F9 hydrogel was assessed following subcutaneous injection. [(18) F]FPCA-F9 demonstrated high plasma stability and primarily renal excretion; [(18) F]FPCA-F9 when in solution and injected into the bloodstream displayed prompt bladder uptake (53.4 ± 16.6 SUV at 20 minutes postinjection) and rapid renal excretion, whereas [(18) F]FPCA-F9 hydrogel, formed by co-assembly of [(18) F]FPCA-F9 monomer with unfunctionalised F9 peptide and injected subcutaneously, showed gradual bladder accumulation of hydrogel fragments (3.8 ± 0.4 SUV at 20 minutes postinjection), resulting in slower renal excretion. Gradual disaggregation of the F9 hydrogel from the site of injection was monitored using FITC-F9 hydrogel in healthy mice (60 ± 3 over 96 hours), indicating a biological half-life between 1 and 4 days. The in vivo characterisation of F9, both as a gel and a solution, highlights its potential as a biomaterial.
dc.language.isoenen
dc.rightsArchived with thanks to Journal of labelled compounds & radiopharmaceuticalsen
dc.titleIn vivo characterisation of a therapeutically relevant self-assembling (18) F-labelled β-sheet forming peptide and its hydrogel using positron emission tomography.en
dc.typeArticleen
dc.contributor.departmentWolfson Molecular Imaging Centre, Univ of Manchesteren
dc.identifier.journalJournal of Labelled Compounds & Radiopharmaceuticalsen
refterms.dateFOA2018-12-17T15:03:25Z
html.description.abstractPositron emission tomography (PET) and fluorescence labelling have been used to assess the pharmacokinetics, biodistribution and eventual fate of a hydrogel-forming nonapeptide, FEFKFEFKK (F9), in healthy mice, using (18) F-labelled and fluorescein isothiocyanate (FITC)-labelled F9 analogues. F9 was site-specifically radiolabelled with 2-[(18) F]fluoro-3-pyridinecarboxaldehyde ([(18) F]FPCA) via oxime bond formation. [(18) F]FPCA-F9 in vivo fate was evaluated both as a solution, following intravenous administration, and as a hydrogel when subcutaneously injected. The behaviour of FITC-F9 hydrogel was assessed following subcutaneous injection. [(18) F]FPCA-F9 demonstrated high plasma stability and primarily renal excretion; [(18) F]FPCA-F9 when in solution and injected into the bloodstream displayed prompt bladder uptake (53.4 ± 16.6 SUV at 20 minutes postinjection) and rapid renal excretion, whereas [(18) F]FPCA-F9 hydrogel, formed by co-assembly of [(18) F]FPCA-F9 monomer with unfunctionalised F9 peptide and injected subcutaneously, showed gradual bladder accumulation of hydrogel fragments (3.8 ± 0.4 SUV at 20 minutes postinjection), resulting in slower renal excretion. Gradual disaggregation of the F9 hydrogel from the site of injection was monitored using FITC-F9 hydrogel in healthy mice (60 ± 3 over 96 hours), indicating a biological half-life between 1 and 4 days. The in vivo characterisation of F9, both as a gel and a solution, highlights its potential as a biomaterial.


Files in this item

Thumbnail
Name:
Morris_et_al-2017-Journal_of_L ...
Size:
641.2Kb
Format:
PDF
Description:
Full text open access article

This item appears in the following Collection(s)

Show simple item record